Lumos Pharma to Participate in the Cantor Neurology & Psychiatry Conference
Austin, Texas, Sept. 26, 2022 (GLOBE NEWSWIRE) - Lumos Pharma (NASDAQ: LUMO), a biopharmaceutical company, announced its participation in the upcoming Cantor Neurology & Psychiatry Conference on October 6-7.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Austin, Texas, Sept. 26, 2022 (GLOBE NEWSWIRE) - Lumos Pharma (NASDAQ: LUMO), a biopharmaceutical company, announced its participation in the upcoming Cantor Neurology & Psychiatry Conference on October 6-7. Management will engage in a panel discussion titled 'Broken circuits. Modulating the neuroendocrine systems to reestablish equipoise' on October 7 at 10:10 AM PT. Additionally, one-on-one meetings will be available on both conference days. Lumos Pharma is advancing its oral therapeutic candidate LUM-201 for Pediatric Growth Hormone Deficiency through Phase 2 clinical trials.
Details
News Market Reaction – LUMO
The recorded move for LUMO in the trading session of this news was -0.47%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
AUSTIN, Texas, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that Lumos Pharma management will participate in a panel discussion and host one-on-one meetings at the Cantor Neurology & Psychiatry Conference in October.
| Event: | Cantor Neurology & Psychiatry Conference – October 6th - 7th | |
| Panel: | “Broken circuits. Modulating the neuroendocrine systems to reestablish equipoise.” Friday, October 7th at 10:10-11:10 AM PT (1:10-2:10 PM ET) | |
| 1x1 Meetings: | Management will be available for one-on-one meetings October 6th & 7th |
The panel presentation will be available only to conference participants and will not be webcast. To schedule a virtual or in-person meeting with Lumos Pharma management during the conference, please contact your Cantor sales representative.
About Lumos Pharma
Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, a PK/PD trial, the OraGrowtH212 Trial, and a switch trial, the OraGrowtH213 Trial for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to recombinant growth hormone injections that PGHD patients otherwise endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.
Investor & Media Contact:
Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com
Source: Lumos Pharma, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.